Targeted regulation of MiR-98 on E2F1 increases chemosensitivity of leukemia cells K562/A02

Huang, Yun; Hong, Xiuli; Hu, Jian; Lu, Quanyi

doi:10.2147/ott.s126819

Cited by 21 publications

(22 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This represents an opportunity to avoid severe side-effects of cancer treatments by using lower chemotherapy dosages. Acute myeloid leukemia, lung cancers, and chemoresistant epithelial ovarian cancers are characterized by a reduced let-7 resulting in nonresponse to chemotherapy [38][39][40][41][42][43]. Interestingly, decreased expression of let-7 was associated with significantly shorter survival after resection and may have a prognostic impact on the survival of surgically-treated lung cancer patients [44].…”

Section: Discussionmentioning

confidence: 99%

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

et al. 2020

View full text Add to dashboard Cite

The most common histological type of thyroid cancer is papillary thyroid carcinoma (PTC). Radical resection of the thyroid gland is currently the recommended method of treatment. Almost 75% of thyroidectomies performed just for diagnostic purposes are benign. Thus, the confirmation of innovative and more precise noninvasive biomarkers holds promise for the detection of PTC, which may decrease the number of unnecessary thyroid lobectomies. In this work, using the droplet digital PCR (ddPCR) method, we have analyzed the level of five miRNAs (let-7a, let-7c, let-7d, let-7f, and let-7i) in the plasma of patients with PTC and compared them with those of a healthy control group to investigate whether miRNAs also have value in the management of PTC. Levels of four miRNAs, namely let-7a, let-7c, let-7d, and let-7f, were significantly higher in PTC patients than healthy controls. Thus, the analysis of circulating let-7 can be a useful tool and support the currently used methods for PTC diagnosis. However, our observation requires further research on a larger patient group.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Let - 7 levels are directly influenced by therapy, illustrated by let - 7c in acute promyelocytic leukemia: its levels increase in blasts after chemotherapy, then decrease again upon relapse [31]. Chemoresistant epithelial ovarian cancers, lung cancers, and acute myeloid leukemia have reduced let - 7 levels relative to chemo-sensitive cells, resulting in non-response to chemotherapy [32–37]. These are examples of ways that monitoring let - 7 levels could be used to predict drug response or recurrence.…”

Section: Let-7 As Tumor Suppressormentioning

confidence: 99%

Let‐7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer

Chirshev

Oberg

Ioffe

et al. 2019

Clinical & Translational Med

208

183

View full text Add to dashboard Cite

Abnormal regulation and expression of microRNAs (miRNAs) has been documented in various diseases including cancer. The miRNA let - 7 (MIRLET7) family controls developmental timing and differentiation. Let - 7 loss contributes to carcinogenesis via an increase in its target oncogenes and stemness factors. Let - 7 targets include genes regulating the cell cycle, cell signaling, and maintenance of differentiation. It is categorized as a tumor suppressor because it reduces cancer aggressiveness, chemoresistance, and radioresistance. However, in rare situations let - 7 acts as an oncogene, increasing cancer migration, invasion, chemoresistance, and expression of genes associated with progression and metastasis. Here, we review let - 7 function as tumor suppressor and oncogene, considering let - 7 as a potential diagnostic and prognostic marker, and a therapeutic target for cancer treatment. We explain the complex regulation and function of different let - 7 family members, pointing to abnormal processes involved in carcinogenesis. Let - 7 is a promising option to complement conventional cancer therapy, but requires a tumor specific delivery method to avoid toxicity. While let - 7 therapy is not yet established, we make the case that assessing its tumor presence is crucial when choosing therapy. Clinical data demonstrate that let - 7 can be used as a biomarker for rational precision medicine decisions, resulting in improved patient survival.

show abstract

“…Mir-98 could negative regulate the expression of tumor suppressor gene FUS1b in lung cancers 29. In leukemia, it was found that miR-98 upregulation could improve chemotherapy-sensitivity and decrease leukemia cell proliferation by inhibiting E2F1 expression 30. In the present study, miR-98 is associated with "definitive hemopoiesis", "negative regulation of myeloid cell differentiation", "signaling pathways regulating pluripotency of stem cells", and they play an important role in hematopoiesis, which suggests that miR-98 may play a prognostic role in leukemia by interacting with genes involved in these functional pathways.…”

Section: Discussionmentioning

confidence: 99%

High expression of MiR-98 is a good prognostic factor in acute myeloid leukemia patients treated with chemotherapy alone

Hu¹,

Cheng²,

Pang³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

It has been demonstrated that microRNA-98 (miR-98) is dysregulated in multiple types of solid tumors, but its expression and impact in acute myeloid leukemia (AML) is unclear. To explore the prognostic role of miR-98 in AML, 164 AML patients with the miR-98 expression data were extracted from The Cancer Genome Atlas (TCGA) database and enrolled in this study. First, patients were divided into chemotherapy-only (chemotherapy) group and allogeneic hematopoietic stem cell transplant (allo-HSCT) group. Each group was then divided in two groups by the median expression level of miR-98. In chemotherapy group, high miR-98 expression was associated with longer event-free survival (EFS, P = 0.003) and overall survival (OS, P = 0.004), but in allo-HSCT group, EFS and OS were not significantly different between high and low miR-98 expressers. Second, All patients were divided in two groups by the median expression level of miR-98. In low miR-98 expressers, those treated with allo-HSCT had longer EFS (P = 0.001) and OS (P < 0.001) than chemotherapy, but in high miR-98 expressers, survival was independent from treatment modalities. Gene ontology enrichment analysis indicated that the genes associated with miR-98 expression were mainly concentrated in “definitive hemopoiesis”, “negative regulation of myeloid cell differentiation” and “signaling pathways regulating pluripotency of stem cells” pathways. In conclusion, our results indicated that high miR-98 expression confers good prognosis in AML patients treated with chemotherapy alone. Patients with low miR-98 expression may benefit from allo-HSCT.

show abstract

Targeted regulation of MiR-98 on E2F1 increases chemosensitivity of leukemia cells K562/A02

Cited by 21 publications

References 34 publications

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

Let‐7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer

High expression of MiR-98 is a good prognostic factor in acute myeloid leukemia patients treated with chemotherapy alone

Contact Info

Product

Resources

About